Combining high-dose brachytherapy with stereotactic body radiation for prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and effectiveness of combining Stereostatic Body Radiation Therapy (SBRT) with high-dose-rate (HDR) brachytherapy for patients with localized unfavorable-intermediate or higher risk prostate cancer. The study will assess the toxicity and therapeutic efficacy of this combination approach, which is designed to reduce the number of treatments while improving biochemical progression-free survival. A total of 53 patients will be enrolled, all of whom will undergo specific imaging evaluations to confirm eligibility and assess nodal involvement risk. The trial hypothesizes that this innovative treatment strategy will yield an acceptable toxicity profile and enhance patient outcomes compared to traditional methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histopathologically proven diagnosis of local unfavorable intermediate or higher risk prostate cancer as defined by NCCN risk group criteria. Biopsies will be confirmed by UNMC pathology review if collected outside our institution.
2. No prior definitive treatment or intervention received.
3. Life expectancy of more than 10 years as estimated by the treating physician.
4. Negative evaluation lymph node involvement or distant metastatic disease on abdominopelvic CT, prostate MRI, and/or PSMA PET.
5. Negative evaluation of osseous metastatic disease via bone scan or PSMA PET scan.
6. Greater than or equal to 15% nodal involvement risk predicated on publicly available MSKCC pre-prostatectomy nomogram.
7. Karnofsky performance status ≥ 80 within 30 days prior to registration.
8. Age ≥ 19 years.
9. Clinically determined to be a candidate for HDR brachytherapy.
10. Patient must be able to provide study-specific informed consent prior to study entry.

Exclusion Criteria:

1. American Urological Association Urinary Symptom Score (AUA score) ≥ 15.
2. Large prostate volume relative to pelvic arch width that can hinder proper placement of applicator insertion. To be done by MRI, TRUS, and/or physical exam for size, by CT A/P or MRI for arch interference. Specifically, prostates must be no greater than 75 cc in size as decerned by MRI, TRUS, or physical exam. Potential for pubic arch interference will be decerned by the treating radiation oncologist based on MRI and/or CT imaging.
3. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
4. Relative or absolute contraindications to radiation therapy as determined by the treating physician. These include, but not limited to, inflammatory bowel disease, connective tissue disorders (systemic lupus erythematosus, scleroderma, etc.), genetic disorders that risk increase sensitivity to radiation therapy.
5. Medical conditions that, in the opinion of the investigator could compromise patient safety.
6. Prior invasive malignancy other than prostate cancer (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year.
7. History of rectal surgeries.
8. Recent major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to registration.
9. History of Urolift.
10. Contraindications to general anesthesia.
11. Preexisting rectal fistula.

Where it's running

• University of Nebraska Medical Center
  Omaha, Nebraska, United States Recruiting

Study contacts

• Principal investigator: Michael J Baine, MD — University of Nebraska
• Study coordinator: Heather D Mittelstedt, RN
• Email: hmittelstedt@unmc.edu
• Phone: 402-559-8287

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating VB15010 Tablets for Advanced Solid Tumors

  This study is testing a new tablet called VB15010 to see if it can help people with advanced solid tumors and specific genetic mutations feel better and fight their cancer.

  Recruiting Phase 1/2 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · Jinan, Shandong · NCT06819215

• Testing HS-10502 for advanced solid tumors

  This study is testing a new drug called HS-10502 to see if it can help people with advanced solid tumors that have certain genetic mutations and who haven't had success with standard treatments.

  Recruiting Phase 1 Jiangsu Hansoh Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT05740956

• Developing a markerless tracking method for real-time tumor motion measurement during radiation therapy

  This study is testing a new way to track tumor movement during radiation therapy without using markers, to see if it can help doctors target the treatment more accurately for cancer patients.

  Recruiting University of Sydney · Saint Leonards, New South Wales and 3 other locations · NCT05184790

• Profiling imaging factors in prostate cancer treatment outcomes

  This study is trying to see if special MRI scans can help doctors better understand and treat prostate cancer in men aged 18 and older.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03354416

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.